Sirolimus Eluting Stent is indicated for improving luminal diameter and reducing restenosis for treatment of coronary artery lesions in native coronary arteries. Safety and efficacy of this stent in humans has been established in randomised clinical trials with 4 years follow-up.
Drug-eluting stent product coats with Rapamycin (Sirolimus), the biodegradable component polylactide (PLA).
The new stent delivery system:
- The new designed luer
- The new distal shaft
- The new designed luer 
- The new flexible tip